« All Events

  • This event has passed.

Research Seminar: Insights into the clonal evolution of myeloid neoplasms from human induced pluripotent stem cell models – Dr. Eirini Papapetrou

June 18 @ 10:00 am - 11:00 am PDT
Join Virtually

 

Meeting 244 087 954 221 893
Passcode: ZF7pR2Sg

Location: Diamond Family Lecture Theatre, BC Cancer Research Institute (Main Floor, 675 West 10th Avenue, Vancouver) + Microsoft Teams

This talk will highlight how human induced pluripotent stem cells (iPSCs) are being used to model the progression of myeloid malignancies, from premalignant conditions such as clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). By combining patient-derived cell reprogramming with CRISPR/Cas9 gene editing, these models enable precise genotype-to-phenotype studies and functional validation in controlled systems. Dr. Papapetrou will present recent findings on the role of RAS pathway mutations in therapy resistance and relapse in AML, as well as the contribution of type I interferon signaling to clonal fitness in TET2-mutated hematopoietic stem and progenitor cells.

 

Dr. Eirini Papapetrou’s Biography:

Eirini Papapetrou, MD, PhD, is a Professor of Oncological Sciences, Hematology and Medical Oncology and the founding Director of the Center for Advancement of Blood Cancer Therapies at the Icahn School of Medicine at Mount Sinai. She received her MD and PhD from the University of Patras, Greece, and completed clinical training in hematology followed by postdoctoral research at Memorial Sloan-Kettering Cancer Center.
Dr. Papapetrou is a pioneer in the development of patient-derived iPSC models for studying myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), as well as premalignant conditions. Her work integrates stem cell biology, genome editing, and functional genomics to uncover disease mechanisms and identify therapeutic targets.
Her research has led to major advances in understanding clonal evolution and treatment resistance in blood cancers, and her laboratory’s iPSC models are widely used across the international research community. She is the recipient of numerous prestigious awards, including the ASGCT Outstanding New Investigator Award, the Damon Runyon-Rachleff Innovation Award, and the Pershing Square Sohn Prize, and she is an elected member of the American Society for Clinical Investigation. Her research program has been continuously funded by the NIH for over 15 years.

Details

  • Date: June 18
  • Time:
    10:00 am - 11:00 am PDT
  • Event Categories: ,

Organizer

  • The BC Cancer Research Institute and UBC’s School of Biomedical Engineering (SBME)

Venue

  • Diamond Family Lecture Theatre, BC Cancer Research Institute (Main Floor, 675 West 10th Avenue, Vancouver)